Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732940 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by Human Genome Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00732940: Clinical Trial Phase 2 study, sponsored by Human Genome Sciences.
NCT00732940 is a Phase 2 study that was terminated before completion, run by Human Genome Sciences. The registered enrollment target is 56 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00732940, a Phase 2 study, was terminated before completion, sponsored by Human Genome Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.
Primary Outcome
SEE ALSO ADVERSE EVENTS RESULTS SECTION
Interventions
- DRUG Belimumab 100 mg SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Why NCT00732940 stopped before completion
NCT00732940 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which Belimumab 100 mg SC is the first listed.
NCT00732940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00732940 about?
NCT00732940 is a clinical study titled "Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)". The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.
What is the current status of trial NCT00732940?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2008-10. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00732940?
The interventions under investigation include: Belimumab 100 mg SC (DRUG).
Who is sponsoring clinical trial NCT00732940?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00732940's enrollment target sits among peer trials
56 1146th of 2000 higher than 848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia